United States

Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

8 Dec 2016
Change (% chg)

$0.38 (+0.30%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Alexion Pharmaceuticals Inc completes rolling BLA submission to U.S. FDA for Asfotase Alfa as treatment for patients with Hypophosphatasia
Tuesday, 30 Dec 2014 06:30am EST 

Alexion Pharmaceuticals Inc:Says completion of rolling submission of Biologics License Application (BLA) to U.S. (FDA) for asfotase alfa, an investigational, first-in-class enzyme replacement therapy for the treatment of hypophosphatasia (HPP).Says HPP is genetic, chronic and progressive ultra-rare metabolic disease that can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death (1-5).  Full Article

BRIEF-Alexion Pharmaceuticals announces new data

* Alexion Pharmaceuticals Inc - new data from an analysis of patients enrolled in global atypical hemolytic uremic syndrome (aHUS) registry